Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction-Reference-Cited by-同舟云学术

Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction

Author:

Lin Chenyu¹²^ORCID,Anderson Clare E.¹³,Scobie Micaela R.⁴,Rodgers Thomas D.¹²,Kelley Michael J.¹⁵⁶,Friedman Daphne R.¹⁵⁶

Affiliation:

1. Division of Hematology‐Oncology Durham VA Health System Durham North Carolina USA

2. Division of Hematologic Malignancies and Cellular Therapy Duke University School of Medicine Durham North Carolina USA

3. Department of Medicine Duke University School of Medicine Durham North Carolina USA

4. National Precision Oncology Program US Veterans Affairs Administration Washington District of Columbia USA

5. National Oncology Program Office US Veterans Affairs Administration Washington District of Columbia USA

6. Division of Medical Oncology Duke University School of Medicine Durham North Carolina USA

Funder

National Heart, Lung, and Blood Institute

Publisher

Wiley

Link

Reference6 articles.

1. HIGHLIGHTS OF PRESCRIBING INFORMATION: IMBRUVICA.U.S. Food and Drug Administration.2013.

2. HIGHLIGHTS OF PRESCRIBING INFORMATION: BRUKINSA.U.S. Food and Drug Administration.2019.

3. HIGHLIGHTS OF PRESCRIBING INFORMATION: CALQUENCE.U.S. Food and Drug Administration.2017.